These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 26668268)

  • 1. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
    Kim MH; Kim J; Hong H; Lee SH; Lee JK; Jung E; Kim J
    EMBO J; 2016 Mar; 35(5):462-78. PubMed ID: 26668268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradicating tumor drug resistance at its YAP-biomechanical roots.
    Zanconato F; Piccolo S
    EMBO J; 2016 Mar; 35(5):459-61. PubMed ID: 26711176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
    Lin L; Sabnis AJ; Chan E; Olivas V; Cade L; Pazarentzos E; Asthana S; Neel D; Yan JJ; Lu X; Pham L; Wang MM; Karachaliou N; Cao MG; Manzano JL; Ramirez JL; Torres JM; Buttitta F; Rudin CM; Collisson EA; Algazi A; Robinson E; Osman I; Muñoz-Couselo E; Cortes J; Frederick DT; Cooper ZA; McMahon M; Marchetti A; Rosell R; Flaherty KT; Wargo JA; Bivona TG
    Nat Genet; 2015 Mar; 47(3):250-6. PubMed ID: 25665005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
    Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
    Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
    Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
    Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation.
    Oku Y; Nishiya N; Sugiyama S; Sato H; Uehara Y
    Anticancer Res; 2018 Jun; 38(6):3471-3476. PubMed ID: 29848699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes.
    Komatsu N; Kajiya M; Motoike S; Takewaki M; Horikoshi S; Iwata T; Ouhara K; Takeda K; Matsuda S; Fujita T; Kurihara H
    Stem Cell Res Ther; 2018 Dec; 9(1):342. PubMed ID: 30526677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP.
    Choe MH; Yoon Y; Kim J; Hwang SG; Han YH; Kim JS
    Cell Death Dis; 2018 May; 9(6):640. PubMed ID: 29844307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
    Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
    J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actin remodelling factors control ciliogenesis by regulating YAP/TAZ activity and vesicle trafficking.
    Kim J; Jo H; Hong H; Kim MH; Kim JM; Lee JK; Heo WD; Kim J
    Nat Commun; 2015 Apr; 6():6781. PubMed ID: 25849865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer.
    Ando T; Charindra D; Shrestha M; Umehara H; Ogawa I; Miyauchi M; Takata T
    Oncogene; 2018 Jan; 37(2):263-270. PubMed ID: 28925394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
    Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
    Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.
    Hu W; Jin L; Jiang CC; Long GV; Scolyer RA; Wu Q; Zhang XD; Mei Y; Wu M
    Cell Death Dis; 2013 Nov; 4(11):e914. PubMed ID: 24201813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAZ and YAP are frequently activated oncoproteins in sarcomas.
    Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
    Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
    Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
    Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
    Vergani E; Vallacchi V; Frigerio S; Deho P; Mondellini P; Perego P; Cassinelli G; Lanzi C; Testi MA; Rivoltini L; Bongarzone I; Rodolfo M
    Neoplasia; 2011 Dec; 13(12):1132-42. PubMed ID: 22241959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
    Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
    Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.
    Choi J; Landrette SF; Wang T; Evans P; Bacchiocchi A; Bjornson R; Cheng E; Stiegler AL; Gathiaka S; Acevedo O; Boggon TJ; Krauthammer M; Halaban R; Xu T
    Pigment Cell Melanoma Res; 2014 Mar; 27(2):253-62. PubMed ID: 24283590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboxane A2 Activates YAP/TAZ Protein to Induce Vascular Smooth Muscle Cell Proliferation and Migration.
    Feng X; Liu P; Zhou X; Li MT; Li FL; Wang Z; Meng Z; Sun YP; Yu Y; Xiong Y; Yuan HX; Guan KL
    J Biol Chem; 2016 Sep; 291(36):18947-58. PubMed ID: 27382053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.